GAL2R mediated the neuroprotective effect promoted by GAL after injury and also activated PKC, PLC and ERK via Gq/11 [17,68,88]; this means that after binding to GAL2R, GAL agonists could be used to treat neurodegenerative diseases (e.g., multiple sclerosis) [49]. The gene discussed is GAL; the disease is neurodegenerative disease.